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Abstract: Tuberous Sclerosis Complex is a multisystem disorder exhibiting a wide range of manifestations characterized 
by tumour-like lesions called hamartomas in the brain, skin, eyes, heart, lungs and kidneys. Tuberous Sclerosis Complex 
is genetically determined with an autosomal dominant inheritance and is caused by inactivating mutations in either the 
TSC1 or TSC2 genes. TSC1/2 genes play a fundamental role in the regulation of phosphoinositide 3-kinase (PI3K) signal-
ling pathway, inhibiting the mammalian target of rapamycin (mTOR) through activation of the GTPase activity of Rheb. 
Mutations in TSC1/2 genes impair the inhibitory function of the hamartin/tuberin complex, leading to phosphorylation of 
the downstream effectors of mTOR, p70 S6 kinase (S6K), ribosomal protein S6 and the elongation factor binding protein 
4E-BP1, resulting in uncontrolled cell growth and tumourigenesis.  
Despite recent promising genetic, diagnostic, and therapeutic advances in Tuberous Sclerosis Complex, continuing re-
search in all aspects of this complex disease will be pivotal to decrease its associated morbidity and mortality. In this re-
view we will discuss and analyse all the important findings in the molecular pathogenesis of Tuberous Sclerosis Complex, 
focusing on genetics and the molecular mechanisms that define this multisystemic disorder.  
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INTRODUCTION 
  Tuberous Sclerosis Complex (TSC) is a dominantly in-
herited disease of high penetrance, characterized pathologi-
cally by the presence of hamartomas (tumour-like lesions) in 
multiple organ systems. Well known clinical manifestations 
include epilepsy, learning difficulties, behavioural problems, 
and skin lesions. Many patients have renal lesions, usually 
angiomyolipomas; cysts, polycystic renal disease, and renal 
carcinoma can also occur. Approximately one in 8,000 adults 
and one in 6,000 newborns are affected by TSC. Although 
TSC is often inherited, new mutations have been implicated 
in up to 75% of all cases. Males and females are equally 
likely to have TSC and the chance of passing it on to off-
spring is 50%. 
  Identification of the genes causing the condition and 
study of their protein products has shed light on the patho-
genesis of the disease and provided valuable new informa-
tion about signalling pathways regulating protein synthesis 
and cell growth. There is now the exciting possibility of drug 
therapy for some of the manifestations of the disease. 
  This review highlights the most significant concepts in 
the genetics and the molecular biology of TSC with empha-
sis on new advances in the knowledge of its pathophysi-
ological mechanisms, the contribute given by animal models, 
and the role of rapamycin in TSC pharmacological therapy. 
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CLINICAL OVERVIEW OF TUBEROUS SCLEROSIS 
COMPLEX 
  The clinical features of TSC have been reviewed in detail 
[1,  2]. Multisystem involvement in TSC results in a wide 
range of manifestations [3, 4].  
Neurological Phenotype 
  The commonest presentation is with seizures in infancy 
or early childhood, particularly infantile spasms. Partial and 
generalized seizures, atonic seizures (drop attacks) and myo-
clonic seizures also occur with the pattern of seizures evolv-
ing through childhood. A population-based study estimated 
that around 80% of children with TSC have epilepsy [5] and 
a prevalence of mental retardation of 44% which in two 
thirds of cases was profound (IQ<21). There is a strong as-
sociation between mental retardation and epilepsy so that 
significant learning disability is very rare in patients with no 
history of seizures [5,6]. Risk factors for mental retardation 
include onset of seizures before 12 months of age, poor epi-
lepsy control and infantile spasms. Infantile spasms develop 
in approximately one third of TSC patients and may be the 
initial symptom in almost 70% of affected infants that come 
to medical attention [7]. The majority of patients with TSC 
and infantile spasms unfortunately go on to develop other 
seizure types. Behaviour problems are common in TSC, par-
ticularly autism, autistic spectrum disorders, attention deficit 
hyperactivity disorder and sleep disturbance in children [8]. 
  The common brain lesions in TSC are tubers in the cere-
bral cortex and subependymal nodules (SEN) along the lat-
eral walls of the lateral ventricles [3]. Histologically, tubers  
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are disorganized areas of cortex lacking the normal lami-
nated architecture. Large cells resembling astrocytes but 
positive for both glial and neuronal markers are a conspicu-
ous feature. SEN comprise a mixture of vascular stroma and 
astrocytic-like cells, some of which are large resembling 
those in tubers. Tubers may be associated with underlying 
white matter abnormalities such as migration lines [9]. Indi-
viduals with mental retardation tend to have more tubers 
than those with normal intelligence [6, 9] and it has been 
suggested that autism spectrum disorder is particularly asso-
ciated with tubers in the temporal lobes [10]. SEN usually 
remain dormant throughout life, but they can increase in 
size, developing into a subependymal giant cell astrocytoma 
(SEGA) that occurs in 6–14% of TSC cases with the peak 
incidence in later childhood and adolescence.  
Renal Lesions 
  The renal manifestations of TSC include angiomyolipo-
mas (AMLs), simple cysts, polycystic kidney disease, and 
renal-cell carcinoma. [11] These lesions likely arise in in-
fancy or early childhood, increasing in size and number with 
age [12]. After neurologic complications, renal involvement 
is the second most common cause of morbidity and mortality 
in TSC [11]. AMLs are found in as many as 80% of TSC 
patients but are typically asymptomatic [11,12]. AML be-
longs to the family of perivascular epithelioid cell tumours 
and is typically composed of blood vessels, adipose tissue, 
and smooth muscle–like cells.  
  Renal cysts are also very common in TSC occurring in 
17% of children and as many as 47% of adults. Like AMLs, 
they are frequently multiple and bilateral. However, renal 
cysts are more likely to become symptomatic than AMLs 
[11,12]. Polycystic kidney disease may also occur. It is a 
more severe, distinct entity with innumerable cysts that en-
large, replace renal parenchyma, and cause renal insuffi-
ciency and hypertension typically at an early age.  
Cardiac Lesions 
  Cardiac rhabdomyomas are benign tumours which are the 
most common
  childhood tumour involving the heart [3]. 
Cardiac rhabdomyomas
 are detected in  60% of TSC pa-
tients and are often the first
  clinical manifestation of TSC 
[13]. Serial observations have demonstrated
 that the majority 
of these lesions become less prominent over
 time, with some 
disappearing altogether as assessed by ultrasound,
  so that 
surgical resection is performed only when they cause
  life-
threatening complications. Pathologically, rhabdomyoma
 
cells are aberrant glycogen-filled myocytes. Following
 rou-
tine histologic processing, loss of the glycogen leads to
  a 
distinctive appearance referred to as spider cells due to
 the 
radial arrangement of residual sarcoplasm extending out
 
from the nucleus. 
Dermatological Phenotypes 
  Several types of skin lesion can occur in TSC [3]. Hy-
popigmented macules on the trunk and limbs are usually 
present at birth or become apparent during infancy. They can 
take any shape but are classically pointed at one end and 
rounded at the other resembling an ash leaf. Similar lesions 
on the scalp are associated with hypopigmented hair (polio-
sis). By 5 years of age, most children are developing an-
giofibromas on the face in the form of multiple flesh col-
oured or red papules. These typically occur over the nose, 
nasolabial folds, cheeks and chin. Fibrous plaques can de-
velop on the forehead. Shagreen patches, which are raised 
brown or flesh coloured connective tissue naevi, often ap-
pear on the lower back during childhood. In adolescents and 
adults, ungual fibromas in the form of pink or red nodules on 
the finger and toe nails are a common finding. Gingival fi-
bromas also occur. Some adults with TSC develop ‘confetti-
like’ hypopigmentation on the limbs. 
Pulmonary Manifestations 
  Lymphangiomyomatosis (LAM) is a rare disorder of un-
known aetiology caused by proliferation of atypical smooth 
muscle cells in the peribronchial, perivascular, and perilym-
phatic tissues of the lung [14]. LAM occurs almost exclu-
sively in young women, typically presenting between 30 to 
35 years of age. Rare cases of LAM have been reported in 
men, but the occurrence of LAM in men is controversial. 
LAM may occur sporadically but is also closely associated 
with TSC and it may affect up to 26% of female patients. 
Clinically, LAM is a progressive disorder of the lung, caus-
ing dyspnea, spontaneous pneumothorax, hemoptysis, cough, 
chylothorax cor pulmonale, and chest pain, eventually lead-
ing to progressive respiratory failure and death. 
  Histopathologically, LAM causes diffuse cystic destruc-
tion of the tissues of the lung by abnormal spindle-shaped, 
closely packed smooth-muscle cells. Multifocal, micronodu-
lar pneumocyte hyperplasia and clear-cell lung tumours have 
also been found in TSC patients. Renal AMLs are present in 
50% of individuals with sporadic LAM and it has been hy-
pothesized that LAM is the result of metastatic spread of 
benign AML smooth-muscle cells [14].  
Ophthalmologic Manifestations 
  The most common ocular findings in TSC are retinal 
hamartomas, appearing in 40% to 50% of patients [1, 15]. 
Their incidence increases with age. In the vast majority of 
TSC patients, they remain clinically stable and asymptomatic 
[16]. 
GENETICS OF TUBEROUS SCLEROSIS COMPLEX 
  The prevalence of TSC is estimated at 1/10,000, and 
about two-thirds of the cases are sporadic with no family 
history due to new mutational events [17]; the mutation rate 
has been estimated at 2.510
5/gamete [18]. TSC is due to 
inactivating mutations in either of two genes, TSC1 (on chro-
mosome 9q34) or TSC2 (on chromosome 16p13.3). These 
mutations comprise the usual mix of nonsense, missense, 
insertion and deletion mutations, involving nearly all of the 
exons of TSC1 and TSC2  (Table  1). Although clinical 
expression of TSC varies greatly, in its classic form, there is 
100% penetrance. Mutational studies of TSC patients have 
demonstrated that mutations in TSC2 are about five times 
more common than mutations in TSC1 in the sporadic TSC 
population, whereas the ratio is 1:1 in large families with 
multiple generations affected. Correspondingly, TSC1 dis-
ease is milder than TSC2 disease in multiple respects, which 
appears to be due to a reduced rate of second hit events [19-Genetics and Molecular Biology of Tuberous Sclerosis Complex  Current Genomics, 2008, Vol. 9, No. 7    477 
21]. Recently, several families have been described in which 
there are unusually mild manifestations of TSC, with most 
‘affecteds’ not meeting diagnostic criteria, segregating with 
missense mutations in TSC2 [22]. 
  For many years, the prevailing model has been that the 
hamartomas of TSC develop through a two-hit mechanism in 
which there is complete loss of expression of functional 
TSC1 or TSC2, supported by findings of loss of heterozygos-
ity (LOH) in TSC tumour samples [23-26]. However, the 
rate of LOH appears to vary according to lesion type, and 
LOH may not occur in all SEGAs and cortical tubers [24, 
26]. On the other hand, recent evidence suggests that both 
tuber giant cells and SEGA cells have similar immunopheno-
types, and SEGAs commonly sustain two-hit inactivation of 
either TSC1 or TSC2.  
Structure of Hamartin (TSC1) and Tuberin (TSC2)  
  The TSC genes TSC1 and TSC2 were first identified by 
positional cloning strategies. They encode previously un-
known proteins, termed hamartin and tuberin respectively, 
that form a functional complex. 
 The  TSC1 gene consists of 23 exons, of which the last 21 
contain coding sequence and the second is alternatively 
spliced [27]. Maximal promoter activity is present in a 587-
bp region + 77 to -510 bp with respect to the transcription 
start site (TSS) in the TSC1 upstream region. Interestingly, 
this region contains no consensus TATA box or CAAT box. 
However, a 521-bp fragment surrounding the TSS exhibits 
the characteristics of a CpG island which overlaps with the 
promoter region. Putative binding sites for several known 
transcription factors, namely Sp1, E2F, CdxA, GATA, c-Ets, 
HSF2, Ik2, USF and SRY are found in the upstream region 
[28]. 
  Hamartin, the predicted product, comprised 1164 amino 
acids (130 kDa). It had no significant homology to tuberin or 
other known vertebrate proteins but did have significant ho-
mology to a Schizosaccharomyces pombe predicted protein 
[29]. Hamartin is ubiquitously expressed [27], and contains a 
putative transmembrane domain at amino acids 127–144 and 
a coiled coil domain (CCD) spanning amino acids 719–998 
[30]. The amino acid residues 145–510 of hamartin contain 
the function for activation of Rho GTPase, and amino acid 
residues 881–1084 interact with the N-terminal of the ezrin–
radixin–moezin (ERM) family of actin-binding proteins (Fig. 
1) [31, 32]. These ubiquitously expressed proteins crosslink 
cortical actin filaments to the plasma membrane, organising 
the cytoskeleton and acting as substrates for the tyrosine 
kinase of the epidermal growth factor receptor. Hamartin has 
also been shown to interact with neurofilament-L [33]. 
  The TSC2 gene has 41 small exons spanning 45 kb of 
genomic DNA and encodes a 5.5 kb mRNA. Exons 25, 26 
and 31 are subject to alternative splicing [17]. The encoded 
protein tuberin has a full-length isoform of 1807 amino acids 
(198 kDa). A region spanning residues 1517–1674 and en-
coded by exons 34–38 has significant homology to the 
GTPase-activiating proteins (‘GAPs’) human rap1 GAP and 
murine Spa1 (Fig. 1) [30,34]. However, only modest GAP 
activity of tuberin for rap1 and rab5 has been demonstrated 
biochemically.  
 TSC2 contains a calmodulin-binding domain and an oes-
trogen-receptor-a-binding domain [35].  
  The gene for polycystic kidney disease, PKD1, is located 
immediately centromeric to TSC2, accounting for the occur-
rence of both conditions in families with large rearrange-
ments (contiguous gene syndromes) [36]. The C-terminal 
domain within the TSC2 protein was recognized as being 
homologous to other GAP domains when it was cloned in 
1993 [30].  
 TSC1 and TSC2 regions responsible for heterodimerisa-
tion have been identified [37]. The region of hamartin known 
to span the interacting domain with tuberin is within the 
amino acids 302–430, and the first 418 amino acids of tu-
berin contain the binding site for hamartin. Hamartin stabi-
lizes tuberin by inhibiting its interaction with the HERC1 
ubiquitin ligase [38]. Proteasome-mediated degradation of 
tuberin has been shown to be induced via its binding to the 
E6 oncoprotein of the human papillomavirus (HPV16 E6). 
HPV16 E6-induced degradation of tuberin leads to activation 
of S6K [39]. Binding of FIP200 to hamartin was suggested 
to disrupt the TSC protein complex formation [40]. Another 
hamartin binding protein has also been implicated in the 
regulation of the TSC tumour suppressor complex. TBC7 
was reported to enhance ubiquitination and degradation of 
hamartin [41]. 
  The two chaperone proteins, HSCP-70 and HSP70-1, 
bind to tuberin. Chaperone proteins recognise and bind mis-
folded proteins. Increased interactions of both chaperone 
proteins with the disease causing tuberin mutant R611Q have 
Table 1.  Number of Mutation Reported for Tuberous Sclerosis Complex Patients 
Mutation   TSC1   Percentage   TSC2    Percentage 
Substitutions   97   36.3%   380   49.4% 
Insertions   10   3.7%    36   4.7% 
Deletion  117   43.8%   265   34.5% 
Duplication   41   15.4%   80   10.4% 
Insertion/deletions   2   0.8%   8   1.0% 
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been reported [42]. The hamartin/tuberin heterodimeric 
complex formation provides a tentative explanation for the 
similar disease phenotype in TSC patients with mutations in 
either of the two TSC genes.  
  Hamartin and tuberin are coexpressed in cells of several 
organs, such as kidney, brain, lung, and pancreas. Hamartin 
has been reported to interact with Plk1 and to be localized to 
the centrosome. Cdk1 phosphorylates hamartin at several 
sites, of which the phosphorylation at T310 regulates its in-
teraction with Plk1 [43].  
  Tuberin has been described to be localised to the cytosol 
and the membrane fraction within the cytoplasm and to the 
nucleus. Akt-mediated phosphorylation of tuberin has been 
demonstrated to regulate both, the translocation of tuberin 
from the membrane to cytosol and the nuclear/cytoplasmic 
localisation of tuberin [44]. 
Mutations and Polymorphisms 
  The mutation spectra of the TSC genes are very hetero-
geneous and no hotspots for mutations have been reported. 
Indeed, more than 200 TSC1 and 700 TSC2 unique allelic 
variants have been reported [20, 21, 45-48]. There are many 
mutations in each gene that are seen recurrently, but no sin-
gle mutation accounts for more than about 1% of all TSC 
patients. Despite complete penetrance of the disease, pheno-
typic variability can make the determination of disease status 
difficult among family members of affected individuals.  
  The major proportions in both genes are subtle mutations 
composed of nonsense mutations, small deletions and inser-
tions, splice site changes, and, for TSC2, additionally mis-
sense mutations. All these mutations are distributed over the 
entire regions of both genes (Fig. 2). 
  Among the large number of TSC mutations identified as 
disease causing, only a few affect splicing regulatory sites. 
The frequency and nature of TSC splice site mutations re-
ported so far are in agreement with these overall findings: in 
TSC1 they represent 8% and in TSC2 they comprise 12% of 
the total number of identified mutations. Most changes were 
merely assumed to influence the mature transcripts, espe-
cially when they affect highly conserved sequences at 
exon/intron junctions, while few are confirmed on the tran-
script or the protein level. Mayer et al. [49] performed an 
RNA based screening of the entire coding regions of both 
TSC genes applying the protein truncation test (PTT) and 
identified a high proportion of unusual splicing abnormali-
ties affecting the TSC2 gene. Two cases exhibited different 
splice acceptor mutations in intron 9 (IVS9315GCA and 
IVS933CCG) both accompanied by exon 10 skipping and 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Biochemical structure of hamartin and tuberin. 
In this figure are rappresented the regulatory phosphorylation sites and respective kinases responsible for their phosphorylation.  Genetics and Molecular Biology of Tuberous Sclerosis Complex  Current Genomics, 2008, Vol. 9, No. 7    479 
simultaneous usage of a cryptic splice acceptor in exon 10. 
Another splice acceptor mutation (IVS38318ACG) de-
stroyed the putative polypyrimidine structure in intron 38 
and resulted in simultaneous intron retention and usage of a 
downstream cryptic splice acceptor in exon 39. Another pa-
tient bore a CCT transition in intron 8 (IVS8+281CCT) acti-
vating a splice donor site and resulting in the inclusion of a 
newly recognised exon in the mRNA followed by a prema-
ture stop.  
 Nellist  et al. [50] showed that pathogenic tuberin amino-
acid substitutions disrupt the tuberin–hamartin complex and 
subsequently have investigated how these mutations affect 
the role of tuberin in the control of signal transduction 
through mTOR. The R611Q, R611W, A614D, C696Y and 
V769E substitutions [51] disrupted the tuberin–hamartin 
interaction, and prevented the phosphorylation of tuberin by 
PKB, the inhibition of S6 and S6K phosphorylation, and the 
stimulation of Rheb GTPase activity, cause TSC because 
they result in major conformational changes to tuberin. The 
609insS and F615S amino-acid changes play a similar effect, 
but do not completely inactivate tuberin.  
  The N525S and K599M substitutions inhibited the phos-
phorylation of S6K and S6, and increased the GTPase activ-
ity of Rheb. The K599M substitution is a de novo mutation 
[46] and has been shown to reduce the tuberin–dependent 
inhibition of phosphorylation of overexpressed 4E-BP1 [52]. 
However, this effect is weak compared to the V769E tuberin 
variant [53].  
 Recently,  Nellist  et al. [54] found that deletion of iso-
leucine at amino acid residue 820 of TSC2 and the TSC2 
L1511H, C244R and Y598H amino acid substitutions are 
sufficient to cause TSC. The TSC2 R1772C, T993M, S132C, 
F143L and A196T substitutions are rare polymorphisms that 
do not inhibit TSC1–TSC2 function, and do not cause TSC.  
  Previous reports have identified a mutation consisting of 
a 34 bp deletion affecting portions of exon 38 and the adja-
cent intron 38 of TSC2. Roberts et al. [55] found this genetic 
variation in 4 of 800 TSC patients. In every case, the variant 
was present in one unaffected parent of the sporadically af-
fected child. They excluded the possibility of mosaicism in 
the parents with this variant and conclude that this deletion is 
a rare polymorphism that does not cause TSC, but may be a 
modifier of the TSC phenotype. 
  Major genes for TSC and autosomal dominant polycystic 
kidney disease (PKD), TSC2 and PKD1, respectively, lie 
adjacent to each other at chromosome 16p3.3, suggesting a 
role for PKD1 in the etiology of renal cystic disease in TSC. 
  Features of TSC and autosomal dominant PKD have 
been observed in patients with a TSC2-PKD1  contiguous 
gene syndrome. In these patients a large part of the adjacent 
TSC2  and  PKD1 genes has been deleted on one chromo-
some. In a study described by Sampson et al. [56] 17 of 22 
patients with such a deletion have been diagnosed with a 
very severe form of PKD, already manifesting within the 
first year of life. A possible explanation for this severe phe-
notype is a functional link between the TSC2 protein and 
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polycystin-1 in protein sorting as described by Kleymenova 
et al. [57]. The frequency of genomic deletions involving 
only the PKD1-gene is low [58]. Ariyurek et al. [58] ob-
served 4 deletions in 125 patients. In another study a 5-kb 
deletion (region intron 34-3'UTR) and a 2-kb deletion (re-
gion intron 30-34) were found upon analysis in a set of 167 
patients [59]. Furthermore, a 3-kb deletion was reported in 
the region intron 1-exon 5, identified using long-range PCR 
performed on 24 patients [60]. Likely, patients with a dele-
tion that disrupts the PKD1 and TSC2 genes are usually iden-
tified as TSC patients. Mosaicism for deletions involving 
TSC2 and PKD1 was a frequent phenomenon and was asso-
ciated with preserved renal function in some cases. Among 
mosaics, disease severity did not correlate with the fre-
quency of the mutant allele in lymphocytes; the level of mo-
saicism in renal tissue is likely to be more important. Five of 
the 27 unrelated patients studied by Sampson et al. [56] had 
multiple cysts in both kidneys, but no detectable disruption 
of PKD1. All were identified, through ultrasound screening, 
as having renal cystic disease. Large rearrangements of TSC2 
were defined in 3 of these patients. 
  The high degree of variability of TSC clinical manifesta-
tions, including those among related and unrelated patients 
with the same mutation [19], suggests the possibility that 
modifier genes influence disease severity. 
 Because  IFN- has been shown to be a useful mediator of 
tumour regression in animal models of kidney tumours [61, 
62] and because there is a known high-expressing allele of 
IFN- in humans, Dabora et al. [63] examined the relation-
ship between the IFN- genotype and the severity of renal 
disease in TSC patients who had TSC2 mutations; they found 
an association between IFN- allele 2 and the absence of 
kidney AMLs in TSC2 patients.  
  This finding suggests that IFN- allele 2 may be a genetic 
modifier that reduces kidney AMLs development or growth. 
Because allele 2 has been shown to be associated with a 
higher level of IFN-  expression in mitogen-stimulated 
mononuclear cells in vitro [64], it is plausible that this asso-
ciation is due to a reduction in kidney AMLs development in 
the presence of higher levels of IFN-. 
  The enzyme 8-oxoguanine glycosylase 1 (OGG1) repairs 
8-oxo-2-deoxyguanosine residue (8-oxodG) an oxidatively 
damaged promutagenic base. Genetic variations in OGG1 
gene have been shown to modulate DNA repair capacity and 
are related risk of tumour development. Habib et al. [65] 
tried to determine whether genetic variants in OGG1 play a 
role in susceptibility to AML in TSC patients. They identi-
fied showed the presence of significant association between 
the Ser326Cys polymorphism of OGG1 and AML. Moreo-
ver, they also assessed the presence of oxidative DNA dam-
age in kidney sections by immunostaining for 8-oxodG. 8-
OxodG staining was highly abundant in kidney AML tissue 
from TSC patients compared to weak staining in uninvolved 
tissue from the same TSC patients or normal kidney from 
healthy subjects. Taken together, these findings suggest that 
OGG1 Ser326Cys variant of may confer risk for develop-
ment of AMLs by increasing oxidative DNA damage. 
  Following the observation of a TSC patient with a de 
novo reciprocal translocation t(3;12) (p26.3;q23.3), Fahsold 
et al. [66] have undertaken a linkage study in 15 TSC fami-
lies using polymorphic DNA markers neighbouring the 
chromosome breakpoints. Significant lod scores have been 
obtained for markers D12S7 (Zmax = 2.34, theta = 0.14) and 
PAH (phenylalanine hydroxylase) (Zmax = 4.34, theta = 
0.0). In multipoint linkage analysis, the peak lod score was 
4.56 at the PAH gene locus. These data suggest the existence 
of a third gene locus for TSC (TSC3) on chromosome 12q22-
24.1. Dysfunctions of phenylalanine hydroxylase pathway 
might be involved in the pathogenesis of TSC. 
Germ-Line Mosaicism Hypothesis 
  Germ-line mosaicism has been demonstrated in both 
common and uncommon genetic disorders [67]. Because 
most germ-line mutations are likely to be mitotic in origin 
and because the mutation rate multiplied by the number of 
mitoses necessary to form the gametes is 11 [68], germ-line 
mosaicism would be expected to occur to some degree in all 
genetic disorders. Empiric recurrence risks of specific dis-
eases can be estimated, but risks for individual families de-
pend on the percentage of affected gametes in the germ line 
of the parent with mosaicism.  
  Fifteen families with two or more affected children and 
apparently unaffected parents have been reported and are 
thought to illustrate examples of germ-line mosaicism [69, 
70]. Yates et al. [71] have proved germ-line mosaicism for 
TSC2 in one family, by molecular analysis.  
  Unaffected parents who have had a child affected with 
TSC usually are given a low (1%) recurrence risk. Evidence 
that germ-line mosaicism is not an uncommon phenomenon 
would increase the estimated risk in cases of sporadic TSC 
and, thus, would have implications for genetic counselling. 
 Rose  et al. [72] found germ-line mosaicism in five fami-
lies with mutations in the TSC2 gene and in one family with 
the causative mutation in the TSC1 gene. 
MOLECULAR BIOLOGY OF TUBEROUS SCLERO-
SIS COMPLEX 
  Led by seminal studies in Drosophila, the TSC1/TSC2 
complex has been positioned in an ancestrally conserved 
signalling pathway that regulates cell growth. TSC1/TSC2 
receives inputs from at least three major signalling pathways 
in the form of kinase-mediated phosphorylation events that 
regulate its function as a GAP protein [73]: the PI3K-Akt 
pathway, the ERK1/2-RSK1 pathway and the LKB1-AMPK 
pathway.  
 TSC1/TSC2 functions as a GAP towards Rheb, which is a 
major regulator of the mammalian target of rapamycin 
(mTOR). In the absence of either TSC1 or TSC2, high levels 
of Rheb-GTP lead to constitutive activation of mTOR–raptor 
signalling, thereby leading to enhanced and deregulated pro-
tein synthesis and cell growth (Fig. 3). 
TSC Upstream Pathways  
  The pathways signalling through TSC1–2 have multiple 
separate phosphorylation sites. Sites identified so far include 
those for GSK3 (glycogen synthase kinase 3) [74] and 
CDK1 (cyclin dependent kinase 1) [75] on TSC1 and those 
for ERK1/2 (extracellular signal-regulated kinase 1 and 2) 
and RSK1 (p90 ribosomal protein S6 kinase 1) [76-78], Genetics and Molecular Biology of Tuberous Sclerosis Complex  Current Genomics, 2008, Vol. 9, No. 7    481 
MK2 [79], Akt (protein kinase B) [80], AMPK (adenosine 
monophosphate-activated protein kinase) [81] and GSK3 
[82] on TSC2.  
 Inoki  et al. [82] suggested a possible function of TSC2/ 
mTOR signalling in tumourigenesis caused by dysfunction 
of the Wnt pathway and a mechanism by which Wnt stimu-
lates protein synthesis and cell growth. This possibility is 
given by the fact that Wnt stimulates the mTOR signalling 
pathway via inhibiting GSK3 phosphorylation of TSC2.  
  The phosphorylation of tuberin by Akt and MK2 pro-
motes the binding of tuberin with 14-3-3 proteins. 14-3-3 
proteins are members of a group of proteins that specifically 
interact with phosphorylated proteins, facilitating the phos-
phorylation-dependent control of protein activity [83]. De-
tection of a ternary complex of tuberin, hamartin and 14-3-3 
suggests that the tuberin-14-3-3 interaction is compatible 
with tuberin-hamartin binding and that 14-3-3 proteins inter-
act with the tuberin-hamartin complex [84, 85]. A possible 
function of the interaction between 14-3-3 proteins and phos-
phorylated tuberin is to inhibit the formation of tuberin-
hamartin complex, in order to decrease the stability of tu-
berin and release of the activated mTOR [84]. 
 Recently,  Yasui  et al. [86] identified NADE (p75NTR-
associated cell death executor) as a novel interactor protein 
with hamartin. NADE has been shown to mediate NGF-
induced apoptosis in neuronal cells through the interaction 
with p75NTR [87, 88]. Hamartin binds to NADE with its 
coiled coil domain domain. Down-regulation of hamartin 
with TSC1 siRNA led to failure of NGF-induced apoptosis in 
PC12h cells suggesting that the association of hamartin with 
NADE is involved in neuronal cell death, which could ex-
plain why hamartoma cells are not eliminated in TSC. Cur-
rent data supports a model that, apart from receptor tyrosine 
kinases, G protein-coupled receptors are also able to regulate 
tuberin activity [89]. Direct evidence has shown that G i/o - 
and G q -coupled receptors can regulate tuberin phosphoryla-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Tuberous sclerosis complex signalling.  
Figure showing signalling pathways involved in the regulation of TSC complex controlling mammalian target of rapamycin (mTOR) activity.  
PI3K=phosphatidylinositol 3-kinase. PIP2=phosphatidyl-inositol (4,5) biphosphate. PIP3= phosphatidyl-inositol (3,4,5) triphosphate. PDK1= 
phosphoinositide-dependent protein kinase 1. PTEN= Phosphatase and tensin homolog. AKT=Protein kinase B. REDD-1=DNA-damage 
inducible transcript 4 protein. RSK-1=ribosomal protein S6 kinase alpha-1. LKB1=Serine/threonine-protein kinase 11. ERK=extracellular 
signal-related kinase. Rheb=Ras homologue enriched in brain. S6K1=ribosomal protein S6 kinase beta-1. 4E-BP1=eukaryotic translation 
initiation factor 4E-binding protein 1. eEF-2K=elongation factor 2 kinase. CDK1= Cyclin dependent Kinase 1.  482    Current Genomics, 2008, Vol. 9, No. 7  Napolioni and Curatolo 
tion in a PI3K-dependent or –independent manner, while G 
12/13 may have a dual role in regulating tuberin. 
  A recent study has demonstrated that the forkhead tran-
scription factor FoxO is capable of binding to tuberin [90]. 
FoxO binds to an adjacent region near the GAP domain, thus 
inhibiting the GAP activity towards Rheb. 
TSC Downstream Pathways  
  The best understood output pathway is from the GAP 
domain of TSC2, although other downstream pathways are 
also likely. 
  Phosphorylation of several sites on TSC1–2 stimulates 
the GAP function of TSC2, whereas phosphorylation of other 
sites inhibits it [37, 73, 91, 92]. Inhibition of the GAP func-
tion of TSC2 shifts the balance of its substrate Rheb to the 
Rheb-GTP form, which activates the mTOR protein and ul-
timately leads to phosphorylation of ribosomal protein S6 
and 4E-BP1 resulting in increased protein synthesis and cell 
proliferation. TSC1–2 is also proposed to function in cell-
cycle control by regulating the cyclin-dependent kinase in-
hibitor p27 [93]. p27 protein levels are regulated through 
ubiquitin-dependent degradation [94].  
  Skp2 is the F-box protein, which together with other pro-
teins forms an SCF-type E3 ubiquitin ligase complex, whose 
task is to target p27 for degradation by the proteasome [95, 
96]. Neither tuberin nor hamartin are in a complex with Skp2 
and tuberin does not affect Skp2 protein levels, and the 
SCFSkp2 ubiquitin ligase does not regulate tuberin stability. 
However, binding of tuberin to p27 sequesters p27 from 
Skp2 accompanied by a stabilization of the p27 interaction 
with cdk2, and hence, Skp2-induced p27 degradation and 
cell cycle progression is abolished by tuberin’s protective 
binding to p27. The observed binding of the tumour suppres-
sor protein tuberin to the tumour suppressor protein p27 pro-
vides a molecular explanation for the effects of the TSC 
genes on p27 protein stability [97]. Through Rac and Rho, 
TSC1 and TSC2 have a signalling role in the development 
and maintenance of the actin cytoskeleton [31, 32]. 
 Ozcan  et al. [98] found that loss of TSC1 or TSC2 in cell 
lines and mouse or human tumours caused endoplasmic re-
ticulum (ER) stress and activated the unfolded protein re-
sponse. The resulting ER stress played a significant role in 
the mTOR-mediated negative feedback inhibition of insulin 
action and increased the vulnerability to apoptosis 
  Tuberin downregulates the DNA repair enzyme 8-oxo- 
guanine DNA-glycosylase (OGG1) with important func-
tional consequences, compromising the ability of cells to 
repair damaged DNA resulting in the accumulation of the 
mutagenic oxidized DNA, 8-oxo-dG. OGG1 localizes with 
tuberin preferentially in kidney cortex. Loss of tuberin is 
accompanied by the loss of OGG1 contributing to tumourge-
nesis [99]. 
ANIMAL MODELS OF TUBEROUS SCLEROSIS 
 Mouse  and  Drosophila models carrying mutant TSC1 and 
TSC2 alleles have been reported, as has a naturally occurring 
TSC2 mutant rat, the ‘Eker’ rat. These models have provided 
a valuable resource for investigating the functions of TSC1 
and TSC2. 
Eker Rat 
  First described in the 1950s, the Eker rat strain contains a 
germline inactivation of one allele of the gene encoding 
TSC2 and has served as an animal model for hereditary renal 
cell carcinoma [100, 101]. Following the identification of 
TSC1 and TSC2 as genes associated with human disease, 
murine models lacking TSC1 or TSC2 were generated by 
gene targeting [102]. 
  In these models, homozygous TSC1 or TSC2 mutants die 
at an embryonic stage, whereas heterozygous carriers are 
predisposed to tumour formation. These studies confirmed 
the tumour suppressor function of TSC1 and TSC2 as in-
ferred from human genetic analysis of the TSC. 
  In particular, the Eker rat carries an inactivating retro-
transposon insertion mutation in exon 30 of the TSC2 gene 
[103]. It develops bilateral multifocal solid and cystic renal 
adenomas and extra-renal pathology, including uterine leio-
myoma, splenic haemangioma, pituitary adenoma and SEN 
hamartomas in the brain [104]. The phenotype is transmitted 
as an autosomal dominant trait with embryonic lethality in 
the homozygote at days 10–12 with disrupted neuroepithelial 
growth and development [101]. Allelic loss and intragenic 
mutation have been demonstrated in tumours in the Eker rat 
[105] and transgenic expression of TSC2 in the Eker rat and 
Eker tumour cell lines support its tumour-suppressor func-
tion [100]. 
TSC1- and TSC2-Knockout Mice 
  Mice with targeted disruption of TSC1  or  TSC2  have 
been generated and express a phenotype similar to the Eker 
rat [102]. Multiple renal cystadenomas develop and lead to 
renal cell carcinoma in approx. 5–15% of mice by 18–24 
months. Although there is considerable inter-strain variabil-
ity in tumour development this appears to be more rapid in 
TSC2  than  TSC1  heterozygotes. Histologically benign he-
patic haemangiomas and histologically malignant but non-
metastasizing haemangiosarcomas of the limbs and tail also 
occur. Lung adenomas have also been observed, but seem to 
have limited growth potential. Homozygotes die in mid-
gestation (E10.5– E12.5) and exhibit growth failure, hepatic 
hypoplasia, cardiac hypertrophy and anaemia. 
Drosophila 
  The identification of TSC1 and TSC2 homologues in 
Drosophila coincided with an exciting burst of studies that 
implicate a role for the insulin signalling pathway in the con-
trol of cell growth in Drosophila and mammals. Cell growth 
– the process in which cells accumulate mass – is a distinct 
process, which should be distinguished from cell prolifera-
tion, because cell proliferation per se does not necessarily 
drive cell growth [106]. 
  The initial implication of insulin signalling in the control 
of cell size in Drosophila was demonstrated by the fact that 
PI3K (p110) and IRS (chico) are required cell-autonomously 
to promotes cell growth [107, 108]; subsequently, various 
studies showed the involvement of other components of the 
insulin pathway in cell growth, including Akt [109], PTEN 
[110], PDK1 [111] and S6K [112]. Collectively, these stud-
ies demonstrate that downregulation of the insulin pathway Genetics and Molecular Biology of Tuberous Sclerosis Complex  Current Genomics, 2008, Vol. 9, No. 7    483 
leads to decreased cell size, whereas upregulation of this 
pathway results in the opposite phenotype. A unique feature 
of the Drosophila system is that, in this organism, it is possi-
ble to monitor cell growth in ‘mosaic’ animals containing 
genetically mutant cells in an otherwise wildtype genetic 
background; this allows an investigation of whether a given 
gene is required cell-autonomously or non cell-autonomously 
for cell growth 
  Homozygous mutations of the TSC2 gene are lethal to 
Drosophila during larval development. However, TSC2/ 
clones generated in specific tissues exhibit the ‘gigas’ pheno-
type characterized by increased cell and organ size with gen-
erally normal differentiation and morphology [113]. Muta- 
genesis screens revealed that TSC1 mutations also cause a 
gigas-like phenotype [114, 115]. 
Schizosaccharomyces Pombe 
  Extensive homology search fails to identify TSC1 and 
TSC2 homologues in the worm Caenorhabditis elegans or 
the budding yeast Saccharomyces Cerevisiae [116]. At pre-
sent, it is unclear whether this reflects a true absence of such 
molecules or functional homologues of TSC1 and TSC2, in 
these organisms, have diverged beyond recognition by sim-
ple homology search. By contrast, the fission yeast Schizosa- 
ccharomyces pombe contains possible homologues of TSC1 
and TSC2 [116]. Similar to their mammalian counterparts, 
the TSC1 and TSC2 homologues of S. pombe form a protein 
complex. Deletion of the TSC1 or TSC2 genes in this organ-
ism results in similar defects in the localization of amino 
acid permease, nutrient uptake and conjugation. Although 
studies of TSC1 and TSC2 homologues in S. pombe are at an 
early stage, because of the simplicity of this organism and 
the power of genetic analysis, this system clearly has tre-
mendous potential as a genetic model for understanding the 
molecular mechanisms of TSC1 and TSC2 functions. 
RAPAMYCIN: MORE THAN A PROMISE 
  Rapamycin, also referred to as Sirolimus, has powerful 
antiproliferative and immunosuppressant activity [117]. 
Since 1999, it has been United States Food and Drug Ad-
ministration approved for the prophylaxis of organ rejection 
in patients older than 13 years. Rapamycin, discovered in 
1965 from soil samples on Easter Island, known to its in-
digenous population as Rapa Nui, was isolated from Strep-
tomyces hygroscopicus [117]. It was found to be active 
against several strains of yeast and fungi. However, no activ-
ity was observed against gram-positive or gram-negative 
bacteria.  
Rapamycin and Tuberous Sclerosis Complex 
  Studies on sirolimus activity have shown that it binds to 
its intracellular receptor FKBP12 (FK506-binding protein 
12), a member of the family of FK506-binding proteins. It 
has also been demonstrated that the binding of sirolimus to 
FKBP12 is required for the inhibitory effect of sirolimus on 
mTOR function [118]. It has been shown that the sirolimus/ 
FKBP12 complex, but not FK506/FKBP12 complex, binds 
with very high affinity to mTOR. At the same time, FK506 
competitively inhibits the effects of sirolimus that are medi-
ated by mTOR. Unlike most kinase inhibitors, sirolimus does 
not completely inhibit the kinase activity of mTOR [119]. 
Instead, sirolimus/FKBP12 complex activity causes derep-
ression of specific protein phosphatases, which leads to de- 
phosphorylation of mTOR downstream effectors like S6K1 
or 4E-BP1. Therefore, Rapamycin, increasing levels of un-
phosphorylated S6K, causes inhibition of translation, and 
produces cell cycle arrest and the possibility of reduced ha-
martoma formation or regression [120].  
  In addition, many of the skin, brain, and kidney hamar-
tomas seen in TSC, including cutaneous angiofibromas and 
LAM, are vascular and contain an endothelial component. 
  Sirolimus decreased VEGF production, which may also 
be beneficial in these vascular tumours because of its antian-
giogenic effects [117, 120]. Oral sirolimus therapy can also 
induce regression of astrocytomas associated with TSC. Five 
patients with TSC and astrocytomas were treated with oral 
sirolimus at standard immunosuppressive doses (serum lev-
els 5-15 ng/mL) from 2.5 to 20 months and showed astrocy-
toma regression [121]. An open-label clinical trial demon-
strated that AMLs in TSC patients regressed somewhat dur-
ing sirolimus therapy but tended to increase in volume after 
the therapy was stopped [122]. Rauktys et al. [123] have also 
shown that topical administration of rapamycin is an effec-
tive treatment for TSC-related tumours in a mouse model 
demonstrating that transdermal delivery of rapamycin is fea-
sible and topical rapamycin should be further investigated as 
a novel treatment approach for TSC skin disease such as 
facial angiofibromas. 
  If one can establish the prenatal diagnosis of TSC and 
begin using sirolimus early, it may be possible to prevent the 
development of TSC manifestations, similar to the situation 
with early diagnosed and treated phenylketonuria [124]. 
However, the utility of mTOR inhibitors in treating epilepsy 
in TSC has not been investigated in either clinical trials or 
animal models. Zeng et al. [125] recently demonstrated that 
rapamycin has strong efficacy for preventing seizures and 
prolonging survival in Tsc1GFAPCKO mice, a mouse model 
of TSC with conditional inactivation of the Tsc1 gene in glial 
fibrillary acidic protein (GFAP)–positive cells (Tsc1GFAP- 
CKO mice), which develops progressive epilepsy, encepha-
lopathy, and premature death, as well as cellular and molecu-
lar brain abnormalities likely contributing to epileptogenesis.  
CONCLUSION/FUTURE DIRECTIONS 
  Significant progress has been made in the understanding 
of the genetic and pathogenic aspects of this serious and 
multi-system disorder. A multidisciplinary approach is es-
sential for an early, accurate diagnosis and proper manage-
ment of affected individuals. The genetic basis of TSC is 
now well understood and genetic testing is available for the 
majority of families, but better methods need to be devel-
oped for rapid and reliable identification of pathogenic muta-
tions. Key priorities for future research include a better un-
derstanding of functional relationship between TSC1 and 
TSC2 and their pathways and a gained insight into the 
relationships between genotypes and phenotypes.  
  The delineation of the TSC biochemical signalling path-
ways suggest strategies for developing targeted therapies 
including mTOR inhibition, which are being evaluated in 
clinical trials. 484    Current Genomics, 2008, Vol. 9, No. 7  Napolioni and Curatolo 
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